The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Sonoma-Cutrer Vineyards (Brown-Forman)
Advised Brown-Forman, the largest American-owned spirits and wine company, on its sale of Sonoma-Cutrer Vineyards to The Duckhorn Portfolio
Lucky Bucks, LLC
Advised the Term Loan Ad Hoc Group to Lucky Bucks, one of the largest Class B coin operated amusement machine (“COAM”) route operators in Georgia, on Lucky Bucks’ financial restructuring and chapter 11 process
Slayback Pharma LLC
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
Canopy Growth Corporation
Advised Canopy Growth, a leading diversified cannabis company, on a series of agreements, including privately negotiated redemption agreements with certain holders of its unsecured senior notes due July 15, 2023 and agreements with certain of its lenders under its term loan credit agreement dated March 18, 2021, that will have the overall effect of deleveraging the Company’s balance sheet by ~C$437mm over time
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
Lookers Plc
Advising JerseyCo, the indirect Holdco of Alpha Auto Group, a Canadian automotive dealership group, on its acquisition of Lookers Plc, a leading UK automotive dealership group
Interest in Joint Venture with CarepathRx Health System Solutions
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
Flavor Specialty Ingredients division of IFF
Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market
Gaming Services Division of Global Payments
Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm
Clinigen Ltd’s Proleukin
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
Pixelligent Technologies
Advised Pixelligent Technologies, a leading manufacturer of nanocrystal material used in consumer electronic devices, on its growth capital raise
Acreage Holdings
Advising Canopy Growth, a leading diversified cannabis company, on the re-organization and consolidation of its U.S. cannabis assets under a new holding company, Canopy USA, and on related investments and debt repurchase transactions
GI Alliance
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
Recipe Unlimited Corporation
Advising the Special Committee of Recipe Unlimited, the largest full-service restaurant company in Canada, on its go private transaction with Fairfax Financial Holdings
InSinkErator (Emerson Electric)
Advised Whirlpool Corporation on its announced acquisition of InSinkErator, the world’s largest manufacturer of food waste disposers and instant hot water dispensers for home and commercial use from Emerson Electric for cash consideration of $3.0 billion
Sands Family
Advised the Sands Family in connection with the elimination of Constellation Brands' Class B common stock, which included the conversion of each share of Class B common stock into the right to receive one share of Class A common stock plus $64.64 in cash consideration
Theramex
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
Acacia Pharma Group plc
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
Alteon Health
Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions
Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
Alert 360
Advising My Alarm Center, a nationwide provider of security and smart home monitoring services, on the acquisition of Alert 360, a leading competitor in the alarm monitoring industry
Bell's Brewery
Advised Lion, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings, on the acquisition of Bell’s Brewery, a leading US independent craft brewery
Procaps Group
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
Faes Farma, flagship product Bilastine
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America